Effectiveness of BNT162b2 XBB vaccine in the US Veterans Affairs Healthcare System

Aisling R. Caffrey(University of Rhode Island), John M. McLaughlin(Pfizer (United States)), Kerry L. LaPlante(Veterans Health Administration), Luis Jódar(Pfizer (United States)), Evan J Zasowski(Pfizer (United States)), Haley J. Appaneal(University of Rhode Island), Vrishali V. Lopes, Laura Puzniak(Pfizer (United States))

Nature Communications

November 2, 2024

10.1038/s41467-024-53842-w

Cited by 30

Related Papers

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

|The Lancet|2021|1.7k

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

|The Lancet|2021|1.3k

The Effect of Molecular Rapid Diagnostic Testing on Clinical Outcomes in Bloodstream Infections: A Systematic Review and Meta-analysis

|Clinical Infectious Diseases|2016|544

Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis

|Critical Care Medicine|2017|234

A Multicenter Study of ICU Telemedicine Reengineering of Adult Critical Care

|CHEST Journal|2014|219